No published human trials
Clinical Benefits: Supports red blood cell formation and helps prevent megaloblastic anaemia Essential for neurological function and nerve tissue health Plays a key role in DNA synthesis and cell metabolism Supports cognitive function, concentration, and mood regulation Assists in the conversion of homocysteine, supporting cardiovascular health Helps address fatigue and weakness associated with B12 deficiency For patients presenting with deficiency, a loading protocol is typically recommended: weekly injections for three weeks, followed by monthly injections for three months, then a maintenance injection every three months
Hematological: Polycythemia vera Gastrointestinal: Mild transient diarrhea Dermatological: Itching
[1] [3] The compounded nature of this product allows for individualized dosing and administration, which may be advantageous in clinical scenarios where standardized commercial products are not available or appropriate
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and increased by 2.5 mg every 4 weeks up to a maintenance dose of 5-15 mg based on tolerability and therapeutic response